BioSpace News Archive

Lui Franciosi will be monitoring the safety and efficacy of nebulized heparin for the treatment of SARS-CoV-2, i.e., COVID-19.

Immunomic Therapeutics, Inc. announced that the company will present at the 14th Annual Biotech Showcase Event, January 10-12 and January 17-19, virtually.

SCYNEXIS, Inc. announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.

Making CES history, Abbott (NYSE: ABT) presented a keynote at the most influential tech event in the world, the first healthcare company ever to do so.

The allowed patent includes 19 claims, key claims relating to the processing of multiple unique test devices simultaneously in a common drawer, mechanisms for decoding identifiers, and lateral flow test results based on line intensity/color.

The emerging landscape of tyrosine kinase inhibitors have shown to significantly enhance the survival rates in cancer patients owing to their ability to specifically target the genomic alterations which are critical for the progression of cancer.

Milestone Scientific Inc today announced that Dr. Harsh Govil, MD, MPH, whose practice is based in Statesville, NC, has begun incorporating the CompuFlo ® Epidural instrument into his practice for pain management, following a successful evaluation.

Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the H.C. Wainwright BioConnect Conference on Thursday, January 13, 2022 at 7:00 AM ET.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it has completed enrollment into its pivotal trial for the use of the RECELL® System for soft-tissue reconstruction.

Alnylam Pharmaceuticals, Inc. today announced a collaboration with Novartis to leverage Alnylam’s proven, proprietary siRNA technology.